-
Recornea received a grant from the Autonomous Region of Friuli Venezia Giulia
This grant will support key activities aimed at the full validation of the GROSSO ® Reshaper, including clinical protocol refinement, production optimization, regulatory compliance, and the execution of multi-center clinical trials.
-
GROSSO ® Reshaper FIH Trial: New Clinical Site Approved in Italy
The GROSSO ® Reshaper First-In-Human (FIH) trial is expanding its reach in Italy following the approval from the "Comitato Etico Territoriale Lazio Area 3" and the formal authorization from the Italian Ministry of Health.
-
GROSSO ® Reshaper FIH Trial: Enrollment Update and Clinical Progress
The GROSSO ® Reshaper First-In-Human (FIH) study continues to advance its clinical evaluation, with four patients already successfully recruited and treated at the IMO Grupo Miranza in Barcelona, Spain.
-
GROSSO ® Reshaper FIH Trial: Three New Patients Treated in Barcelona
The GROSSO ® Reshaper First-In-Human (FIH) trial has progressed with the treatment of three new patient sat the Institute of Ocular Microsurgery (IMO) in Barcelona, Spain.
-
The patent of the injector for the GROSSO® Reshaper
During the first clinical trial, the implanation of the GROSSO® Reshaper was manually executed.
-
The first Company General Meeting
On 6th June 2025, Recornea successfully organised the first Company General Meeting held at Yatch Club Adriaco, Trieste, Italy.
-
Secured the grant of 2.1 M$ by the US Government and the Medical Technology Enterprise Consortium (MTEC)
We are proud to announce that Recornea has successfully secured a 2.1 M$ grant funded by the US Government
-
Closing the oversubscribed 1.2 M€ seed round with an investment from ENEA Tech e Biomedical
We are proud to announce that Recornea has successfully secured over 1.2 M€ in financing as part of our oversubscribed Seed round
-
First patient treated with the GROSSO® implant as part of the First In Human clinical trial
Working with the Institute of Ocular Micro Surgery (IMO) in Barcelona, Spain, we achieved a very monumental milestone in the First In Human clinical trial.
-
Welcoming on board Dr. Letizia Mansutti, MD, Ophthalmic Surgeon, Angel Investor and Board Member in our company
We are pleased to have on board Dr. Letizia Mansutti, MD, Ophthalmic Surgeon, Angel Investor and Board Member in Recornea.
-
Regulatory approvals to conduct the First In Human Clinical trial and Conducting the Site Initiation Visit to kick-off the activities
We are thrilled to announce that we received regulatory approvals to conduct the First In Human Clinical Trial for our fist-line medical device for the treatment of keratoconus in Spain. Thus, Recornea is entering the clinical phase in humans.
-
Welcoming on board Dr. Rossella Baldini as Clinical Trial Manager in our company
We are very pleased to announce and welcome Dr. Rossella Baldini as a Clinical Trial Manager on board in our team at RECORNEA.
-
Completion of the 6 month follow up of the rabbit study of the GROSSO® implant
Recornea, in collaboration with Prof. Neil Lagali, Professor, Division of Ophthalmology, Department of Biomedical and Clinical Sciences, Linköping University, Sweden conducted the six month follow-up of the rabbit study.
-
First Surveillance Audit of Recornea's ISO 13485:2016 certified Quality Management System
From 30 to 31 January 2024, Recornea had a Surveillance Audit of its ISO 13485:2016 certified Quality Management System by an auditor from the Notifying Body, DQS Medizinprodukte GmbH.
-
Submission of the Clinical Investigation Protocol to Ethics Committee and the AEMPS
Submission of the Clinical Investigation Protocol and all documents needed for authorization to conduct the First In Human Clinical trial to Ethics Committee and the AEMPS.
-
Completion of the pre-clinical testing of the GROSSO® implant
This represents an important milestone in the development of our company moving from pre-clinical stage to the clinical stage with our first product.
